181 related articles for article (PubMed ID: 26745042)
21. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways.
Chen Q; Li W; Wan Y; Xia X; Wu Q; Chen Y; Lai Z; Yu C; Li W
Hepatology; 2012 Jun; 55(6):1820-9. PubMed ID: 22213475
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
[TBL] [Abstract][Full Text] [Related]
23. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
[TBL] [Abstract][Full Text] [Related]
24. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
I Ilyas S; Borad MJ; Patel T; Gores GJ
Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
[TBL] [Abstract][Full Text] [Related]
25. Metformin does not improve survival of cholangiocarcinoma patients with diabetes.
Yang Z; Zhang X; Roberts RO; Roberts LR; Chaiteerakij R
Hepatology; 2016 Feb; 63(2):667-8. PubMed ID: 25833233
[No Abstract] [Full Text] [Related]
26. Anticancer activity using positron emission tomography-computed tomography and pharmacokinetics of β-eudesmol in human cholangiocarcinoma xenografted nude mouse model.
Plengsuriyakarn T; Karbwang J; Na-Bangchang K
Clin Exp Pharmacol Physiol; 2015 Mar; 42(3):293-304. PubMed ID: 25545782
[TBL] [Abstract][Full Text] [Related]
27. Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis.
Deng H; Qian X; Zhang Y; Yu W; Yang P
Dig Dis Sci; 2024 Feb; 69(2):476-490. PubMed ID: 38170336
[TBL] [Abstract][Full Text] [Related]
28. Lobaplatin induces apoptosis and arrests cell cycle progression in human cholangiocarcinoma cell line RBE.
Wang Z; Tang X; Zhang Y; Qi R; Li Z; Zhang K; Liu Z; Yang X
Biomed Pharmacother; 2012 Apr; 66(3):161-6. PubMed ID: 22425181
[TBL] [Abstract][Full Text] [Related]
29. Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma.
Koprowski S; Sokolowski K; Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M
J Surg Res; 2015 Oct; 198(2):434-40. PubMed ID: 25890434
[TBL] [Abstract][Full Text] [Related]
30. Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo.
Xu D; Ma Y; Zhao B; Li S; Zhang Y; Pan S; Wu Y; Wang J; Wang D; Pan H; Liu L; Jiang H
Oncol Rep; 2014 May; 31(5):2063-70. PubMed ID: 24603952
[TBL] [Abstract][Full Text] [Related]
31. Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells.
Jinawath A; Akiyama Y; Sripa B; Yuasa Y
J Cancer Res Clin Oncol; 2007 Apr; 133(4):271-8. PubMed ID: 17294242
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest.
Samukawa E; Fujihara S; Oura K; Iwama H; Yamana Y; Tadokoro T; Chiyo T; Kobayashi K; Morishita A; Nakahara M; Kobara H; Mori H; Okano K; Suzuki Y; Himoto T; Masaki T
Int J Oncol; 2017 Dec; 51(6):1674-1684. PubMed ID: 29075786
[TBL] [Abstract][Full Text] [Related]
33. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
Chung V
Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
[TBL] [Abstract][Full Text] [Related]
34. Sulfated Galactans from Red Seaweed Gracilaria fisheri Target EGFR and Inhibit Cholangiocarcinoma Cell Proliferation.
Sae-Lao T; Tohtong R; Bates DO; Wongprasert K
Am J Chin Med; 2017; 45(3):615-633. PubMed ID: 28385079
[TBL] [Abstract][Full Text] [Related]
35. Metformin sensitizes cholangiocarcinoma cell to cisplatin-induced cytotoxicity through oxidative stress mediated mitochondrial pathway.
Wandee J; Prawan A; Senggunprai L; Kongpetch S; Kukongviriyapan V
Life Sci; 2019 Jan; 217():155-163. PubMed ID: 30528773
[TBL] [Abstract][Full Text] [Related]
36. Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma: Association of diabetes mellitus and cholangiocarcinoma.
Saengboonmee C; Seubwai W; Wongkham C; Wongkham S
Cancer Epidemiol; 2015 Jun; 39(3):274-8. PubMed ID: 25910864
[TBL] [Abstract][Full Text] [Related]
37. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma.
Chen H; Zhu B; Zhao L; Liu Y; Zhao F; Feng J; Jin Y; Sun J; Geng R; Wei Y
Cell Physiol Biochem; 2018; 47(2):641-653. PubMed ID: 29794468
[TBL] [Abstract][Full Text] [Related]
38. Advances in research and application of photodynamic therapy in cholangiocarcinoma (Review).
Li Y; Li Y; Song Y; Liu S
Oncol Rep; 2024 Mar; 51(3):. PubMed ID: 38334150
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
40. The therapeutic effect of KSP inhibitors in preclinical models of cholangiocarcinoma.
Shi Y; Cui X; Jiang T; Pan Y; Lin Y; Feng X; Ding Z; Yang C; Tan Y; Wang H; Dong L
Cell Death Dis; 2022 Sep; 13(9):799. PubMed ID: 36123339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
